Skip to main content
. 2021 Jul 15;11:697950. doi: 10.3389/fonc.2021.697950

Figure 4.

Figure 4

Pimozide sensitizes DOX-resistant cells to DOX by suppressing STAT5a. (A) Survival rate of MCF/DOX cells after treatment with pimozide for 48 h, with the IC50 calculated to be 14.79 μM. (B, C) Expression of p-STAT5 (Try 694), STAT5a and ABCB1 in MCF7/DOX cells after treatment with 0, 1, 2, or 5 μM DOX for 48 h (B) or with 5 μM DOX for 0, 12, 24, 48 or 72 h (C). (D) Survival rate of MCF/DOX cells after treatment with a combination of 0, 1, 2 or 5 μM pimozide and the indicated concentration of DOX for 48 h. (E, F) Apoptosis rate of MCF7/DOX cells after the indicated treatment assessed by flow cytometry (E); bar graphs showing the percentage of apoptotic cells (F). (G) Expression of apoptosis markers in MCF7/DOX cells given the indicated treatments determined by Western blotting. (H, I) Accumulation of DOX in MCF7/DOX cells after treatment with DOX or a combination of DOX and pimozide (H) and quantification (I). (J, K) Western blotting was performed to determine the expression of STAT5a, ABCB1, cleaved PARP, cleaved caspase 7 and cleaved caspase 3 in MCF7/DOX cells treated with DOX and transfected with the indicated vectors. ns, p > 0.05; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.